Loading organizations...
Key people at Alpex Pharma SA.
Alpex Pharma SA is a contract development and manufacturing organization specializing in niche oral solid dosage forms, based in Mezzovico, Switzerland. The company focuses specifically on the research, development, and commercial production of effervescent tablets, granules, and orally disintegrating tablets for global pharmaceutical clients. Operating a Swissmedic and EU GMP-approved manufacturing facility, the firm provides fee-for-service product development alongside the out-licensing of its proprietary formulations in the neuroscience and longevity sectors. Following an acquisition by longevity-focused entrepreneurs in 2020, the enterprise officially merged with Alpen Group on March 28, 2022, under the leadership of executives including Kevin McKenzie and Gabriele Granata. The organization also maintains historical corporate ties to its former acquirer, the drugmaker Elan Pharma. Alpex Pharma SA was originally founded in 1988 by early executive and recognized co-founder Shahbaz Ardalan.
Key people at Alpex Pharma SA.
Alpex Pharma SA is a Swiss research-based pharmaceutical company specializing in end-to-end drug development, formulation, clinical trials, product registration, manufacturing, and global export of innovative pharmaceutical and nutraceutical products.[1][2][3] It focuses on advanced drug delivery technologies like orally disintegrating tablets (ODT or "fast melt"), effervescent tablets, and sustained-release formulations, serving global pharmaceutical partners by addressing unmet needs in areas such as obesity, pain management, respiratory issues, and kidney disease.[1][2][4][6] With 7000 square meters of GMP-compliant facilities in Mezzovico, Ticino, the company generates around $11.3 million in annual revenue and employs about 44-67 people, scaling breakthroughs for aging populations and improved healthcare access.[1][2][4]
Founded in 1988 in Switzerland, Alpex Pharma SA began with a mission to develop medicines for untreated areas, quickly gaining traction when acquired by Irish firm Elan Pharma, which expanded its neuroscience drug development as Elan's Swiss R&D hub.[3] This period saw the creation of multiple proprietary drugs, patents, and unique delivery systems applicable to existing pharmaceuticals, building a global client base among leading pharma companies.[3] In 2020, entrepreneurs acquired the company to scale longevity-focused innovations, blending Alpex's technologies with modern active pharmaceutical ingredients (APIs).[3] Now over 35 years old, it maintains a reputation for Swiss precision, having developed dozens of drugs for demanding global markets under Managing Director Shahbaz Ardalan.[2][3]
Alpex rides the wave of next-generation pharma trends like advanced drug delivery for patient-centric dosing (e.g., no-water ODTs improving adherence) amid rising demand from aging populations, chronic diseases, and global healthcare access.[1][6] Its timing aligns with lifecycle management needs, extending patents via reformulations, and supports biopharma scaling through contract manufacturing for complex APIs.[3][6] In Switzerland's precision pharma ecosystem, Alpex influences by partnering with majors, fostering innovation in underserved areas like respiratory and renal care, and enabling faster global market entry.[1][3]
Alpex is poised to expand its innovation pipeline in longevity and targeted therapeutics, leveraging 35+ years of patents and global partnerships to capture growth in personalized medicine and nutraceuticals.[1][3] Trends like AI-driven formulation, rising obesity/pain markets, and sustainable manufacturing will shape its path, potentially boosting revenue beyond $11.3M via new API integrations and exports.[2][6] Its influence may evolve as a key enabler for big pharma's delivery challenges, solidifying Swiss leadership in scaling medicinal breakthroughs from R&D to market.[1][3]
